Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Several other equities research analysts have also recently commented on CRNX. Jonestrading increased their price objective on Crinetics Pharmaceuticals […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price boosted by Robert W. Baird from $52.00 to $62.00 in a research report sent to investors on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other equities research analysts also recently weighed in on CRNX. Morgan Stanley upped […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. Robert W. Baird currently has an outperform rating on the stock. A number of other research firms have also commented on CRNX. Morgan Stanley increased […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $60.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 18.72% from the stock’s previous […]